CRISIL Equities has assigned a grade of 1/5 to the proposed IPO of Unijules Life Sciences, which indicates that the fundamentals of the IPO are poor relative to other listed equity securities in India, according to research report.
Unijules manufactures and markets allopathic and herbal pharmaceutical branded and non-branded formulations for human and veterinary consumption. The company operates through three divisionsDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
